Infantile Neuroaxonal Dystrophy – Talk Bio

Actionable Insights Powered by AI

Navigating Challenges: Keros and Tempest Aim to Stabilize and Strategize for Growth

2 weeks ago talkbio0Tagged biopharmaceutical sector, Biotechnology, Clinical Trials, Corporate, financial, Infantile Neuroaxonal Dystrophy, Investments, restructuring, stockholder, strategic alternatives

Keros Therapeutics , Strategic alternatives , Financial challenges , Biopharmaceutical sector , Stockholder rights plan , Clinical trials , Tempest Therapeutics , Corporate restructuring , Biotechnology investments

Johnson & Johnson Boosts Talc Settlement by $1.1 Billion Amid Ongoing Negotiations

8 months ago talkbio0Tagged Bankruptcy, Increase, Infantile Neuroaxonal Dystrophy, Johnson and Johnson, Talc Settlement

Johnson & Johnson, Talc Settlement, $1.1 Billion Increase, Cancer Lawsuits, Bankruptcy Plan